Cancer diagnosis impacts patient adherence to diabetes meds

Share this content:
Cancer Diagnosis Impacts Patient Adherence to Diabetes Rx
Cancer Diagnosis Impacts Patient Adherence to Diabetes Rx

(HealthDay News) -- People with diabetes are less likely to take their diabetes medications if they've been diagnosed with cancer, researchers report. The findings were published online Jan. 28 in Diabetologia.

The new study included 16,172 diabetes patients, average age 68, taking drugs to lower blood glucose. Of those patients, 3,281 were diagnosed with cancer. To determine the impact, the researchers analyzed the patients' medication possession ratio (MPR), which represents the amount of medication patients had in their possession over a certain period of time.

A 10 percent decline in MPR translated into three days a month where patients did not take their diabetes medications. At the time of cancer diagnosis, there was an overall 6.3 percent drop in MPR, followed by a 0.20 percent monthly decline following a cancer diagnosis. The researchers also found that MPR rose 2.1 percent after a prostate cancer diagnosis and fell only 0.5 percent after a breast cancer diagnosis. Large drops in MPR occurred among patients with liver (35.3 percent), esophageal (19.2 percent), lung (15.2 percent), stomach, and pancreatic cancers, as well as those with late-stage cancer (10.7 percent). For each extra month after cancer diagnosis, the largest declines in MPR were seen in patients with pancreatic cancer (0.97 percent) and in those with late-stage cancer (0.64 percent).

"Although the impact of cancer was more pronounced among cancers with a worse prognosis and among those with more advanced tumor, node, metastasis stages, the difference in prognosis associated with these cancers seemed to only partly explain the impact of cancer on medication adherence," the authors write. "In future studies, the reason for the decline in MPR needs to be further elucidated among the different cancer types -- is it the patient who prioritizes the fight against cancer or the advice of the physician to stop the treatment?"

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs